Investing-News.Com
Information for Investors

NYMOX PHARM CORP, (NYMX) Stock Ratings - Investing-News.Com
 

 Home   Market News   Analysis   Commentary   Education   Tools   Weekly Report 

Internet Search   Stock Search
   

 

NYMOX PHARM CORP, (NYMX) Stock Rating Learn More

Our Overall Rating on Nymox Pharmaceutical Corporation,  NYMX is BUY
StockPickReport.Com research suggests NYMX's price will move higher than the "open price" the day this rating was initiated.

This analysis is based on short-term stochastic and "relative strength" indicators.

With StockPickReport.Com's "Buy" rating, stochastic and "relative strength" numbers may agree, but not in all cases.

Investors, traders, and other market participants may find this a good opportunity to buy NYMX, "buy calls", or "sell puts".

This may also be an opportunity to raise targets and stop/losses to allow for potential gains (although those gains may not be as signficant as gains experienced in conjunction with a "Strong Buy" rating).

Trading volume seems to be falling and NYMX's closing price moved down during the week before this rating was initiated.

Our BUY Rating on NYMX was issued on 03/25/08

NYMOX PHARM CORP Technical Rating



Ratings Provided by Stock-Letter-Daily.Com

Rate Any Stock
(enter symbol and click)

Stock Rating Definitions

Stock Ratings Home

Sponsored Links:

Software Forces NYMOX PHARM CORP Investors To Buy Low and Sell High The Position Cost Averaging Stock Investing Systems helps LONG-TERM investors in NYMOX PHARM CORP buy low and sell high every time guaranteed. Click Here To Learn More

We Give Precision Entry & Exit Points on NYMOX PHARM CORP. This software is specially designed to give precision entry and exit points on NYMOX PHARM CORP, or any other stock you choose.
Click Here to learn how to take control of your trading.

How To Know When NYMOX PHARM CORP Beats The Street. New Software Offers "One-Click" Stock Picks. The StockPickerRT will pick stocks for you every trading day based on earnings, volume & momentum. Maybe even NYMOX PHARM CORP, if they make the cut.
Click Here & Learn To
Pick Winners In An Uncertain Market



Related Searches: comtex and rumors 2005  merck kgaa v. integra lifesciences ltd.  stockpickerrt 

Research Home


Article Search


Advanced Search

StreetInsider Alerts

Latest Headlines

Nymox Announces NEXUS-1 and NEXUS-2 Phase 3 Trials for NX-1207 Investigational Drug for BPH (Business Wire)

Nymox Reports Third Quarter 2008 Financial Results (Business Wire)

Nymox Reports Positive New Results in 59 Week Study of Drug for Enlarged Prostate (Business Wire)

Nymox NX-1207 Data Presented Today at American Urological Association Meeting in Monterey (Business Wire)

Powerful New Evidence Shows Statin Drugs Reduce Risk of Alzheimer's Disease (Business Wire)

Recent Clinical Trial data for Nymox NX-1207 Drug to Be Presented at American Urological Association Meeting in Monterey on Thursday (Business Wire)

Nymox Nears Completion of New One Year U.S. Study of BPH Drug (Business Wire)

Statins Reduce Risk of Alzheimer's Disease According to New Long-Term Prospective Study (Business Wire)

Nymox NX-1207 Successful Clinical Trial Results Featured in Urology Times (Business Wire)

Nymox Updates NX-1207 Product Development Activities (Business Wire)

  Place Our Content On Your Site!  rss Powered By The Investing System Network
© 2006 Investing-News.Com, All Rights Reserved.